All lobbying filings

TODD STRATEGY GROUP

Lobbying for ASTRAZENECA PHARMACEUTICALS LP · â€‹Biopharmaceutical Company.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · Delaware · House · Senate · $80,000.00 income · posted Apr 20, 2026

Official filing document

Bills named in this filing 3

S 864
HELP Copays Act
HR 1672
Maintaining Investments in New Innovation Act
HR 946
ORPHAN Cures Act

Lobbying activity 2

Medicare/Medicaid

340B Program. Home Infusion for Part B Products. S.864: HELP Copays Act. Medicare Reimbursement for New Technologies.

Health Issues

Pediatric Priority Review Voucher Program. General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672: Maintaining Investments in New Innovation Act. H.R.946: ORPHAN Cures Act. Prescription drug pricing policy.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.